Joachim Rudolph is a Principal Scientist at Genentech, where he serves in a joint appointment between the Discovery Chemistry and Discovery Oncology departments. Prior to working at Genentech, Joachim was a Senior Scientist at Bayer, working as a medicinal chemist at its Germany and US sites. He completed his Bachelor’s and Master's degrees in organic chemistry and biochemistry from the University of Bonn, Germany, and earned his PhD in Professor Manfred Reetz’s group at the Max-Planck Institute in the field of supramolecular chemistry. He performed his postdoctoral studies with Professor Barry Sharpless at Scripps investigating enantioselective metal catalysis reactions. His experiences in the areas of molecular recognition and synthetic methodology primed his interest in medicinal chemistry, which became his career choice.
Joachim has been a project and chemistry team leader at Bayer and Genentech in a broad range of disease areas ranging from antibacterials and metabolic diseases to cancer, and he has a keen interest in developing and deploying innovative approaches to tackle difficult drug targets. Joachim serves as an editor and advisor for several high profile journals, including The Journal of Medicinal Chemistry and ACS Medicinal Chemistry Reviews (oncology section) and has been a member of the AACR Chemistry in Cancer Research steering committee. Joachim has 75 peer reviewed publications and patent applications and has been a presenter and session chair at numerous international meetings.